- Home
- MYNZ
MYNZ
Mainz Biomed N.V.
as 04-24-2025 12:40pm EST
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
| Founded: | 2021 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.2M | IPO Year: | 2021 |
| Target Price: | $14.00 | AVG Volume (30 days): | 119.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -22.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.18 - $8.20 | Next Earning Date: | 05-06-2025 |
| Revenue: | $893,991 | Revenue Growth: | -0.17% |
| Revenue Growth (this year): | 42.95% | Revenue Growth (next year): | -7.43% |
Latest Mainz Biomed N.V. News
MYNZ Breaking Stock News: Dive into MYNZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Medical Device Network
a month ago
Mainz enrols first subject in study to evaluate colorectal cancer test
GlobeNewswire
a month ago
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
MT Newswires
a month ago
Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer
GlobeNewswire
a month ago
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
GlobeNewswire
2 months ago
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
GlobeNewswire
2 months ago
Mainz Biomed Expands into Switzerland with labor team w
GlobeNewswire
2 months ago
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Compare MYNZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYNZ Mainz Biomed N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.